Cargando…

Immune Evasion as the Main Challenge for Immunotherapy of Cancer

Detalles Bibliográficos
Autores principales:	Zagozdzon, Radoslaw, Winiarska, Magdalena, Firczuk, Malgorzata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330814/ https://www.ncbi.nlm.nih.gov/pubmed/35892880 http://dx.doi.org/10.3390/cancers14153622

Ejemplares similares

Selection of an optimal promoter for gene transfer in normal B cells
por: Winiarska, Magdalena, et al.
Publicado: (2017)

Mechanisms of Immune Evasion in Acute Lymphoblastic Leukemia
por: Pastorczak, Agata, et al.
Publicado: (2021)

Triple Combination of Ascorbate, Menadione and the Inhibition of Peroxiredoxin-1 Produces Synergistic Cytotoxic Effects in Triple-Negative Breast Cancer Cells
por: Bajor, Malgorzata, et al.
Publicado: (2020)

Inhibition of autophagy sensitizes cancer cells to Photofrin-based photodynamic therapy
por: Domagala, Antoni, et al.
Publicado: (2018)

Perspectives for 3D-Bioprinting in Modeling of Tumor Immune Evasion
por: Staros, Rafał, et al.
Publicado: (2022)

Immunotherapy and Immune Evasion in Prostate Cancer
por: Thakur, Archana, et al.
Publicado: (2013)

Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives
por: Bobrowicz, Malgorzata, et al.
Publicado: (2019)

New insights into redox homeostasis as a therapeutic target in B-cell malignancies
por: Graczyk-Jarzynka, Agnieszka, et al.
Publicado: (2017)

Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer
por: Wachowska, Małgorzata, et al.
Publicado: (2011)

Immune evasion mechanisms of arenaviruses
por: Ly, Hinh, et al.
Publicado: (2015)

Back from the dead: TIL apoptosis in cancer immune evasion
por: Horton, Brendan L, et al.
Publicado: (2018)

Prospects for NK Cell Therapy of Sarcoma
por: Lachota, Mieszko, et al.
Publicado: (2020)

P1376: IDENTIFICATION OF SURFACEOME CHANGES IN CD19 CAR-T THERAPY-RESISTANT LYMPHOMA CELLS
por: Krawczyk, Marta, et al.
Publicado: (2023)

Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma
por: Trzeciecka, Anna, et al.
Publicado: (2015)

Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy
por: Zhan, Lei, et al.
Publicado: (2020)

Interleukin 12: still a promising candidate for tumor immunotherapy?
por: Lasek, Witold, et al.
Publicado: (2014)

Special Issue “Viral Evasion or Suppression of Host Immunity”
por: Hahm, Bumsuk
Publicado: (2020)

Genomic mechanisms of immune evasion in colorectal cancer: from discovery to clinical practice
por: Grasso, Catherine S., et al.
Publicado: (2018)

Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy
por: Bou-Dargham, Mayassa J., et al.
Publicado: (2020)

Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer
por: Marhelava, Katsiaryna, et al.
Publicado: (2019)

Next frontier in tumor immunotherapy: macrophage-mediated immune evasion
por: Qiu, Yingqi, et al.
Publicado: (2021)

Virus Immune Evasion: New Mechanism and Implications in Disease Outcome
por: Draenert, Rika, et al.
Publicado: (2012)

Special Issue: “Innate Immune Sensing of Viruses and Viral Evasion”
por: König, Renate, et al.
Publicado: (2021)

Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents
por: Bajor, Malgorzata, et al.
Publicado: (2018)

The mechanisms of immune response and evasion by the main SARS-CoV-2 variants
por: Chen, Qiuli, et al.
Publicado: (2022)

Immune Evasion, a Potential Mechanism of Trichothecenes: New Insights into Negative Immune Regulations
por: Wu, Qinghua, et al.
Publicado: (2018)

In Situ Programming of CAR-T Cells: A Pressing Need in Modern Immunotherapy
por: Śledź, Marta, et al.
Publicado: (2023)

Challenges and Opportunities for Effective Cancer Immunotherapies
por: Slaney, Clare Y., et al.
Publicado: (2020)

Identification and Validation of an Immune Evasion Molecular Subgroup of Patients With Colon Cancer for Implications of Immunotherapy
por: Zhang, Hongbin, et al.
Publicado: (2022)

Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer
por: Lee, Joyce V., et al.
Publicado: (2022)

Synergistic effect of glutathione and IgG4 in immune evasion and the implication for cancer immunotherapy()
por: Zhang, Weifeng, et al.
Publicado: (2023)

Current understanding of cancer stem cells: Immune evasion and targeted immunotherapy in gastrointestinal malignancies
por: An, Junyi, et al.
Publicado: (2023)

DUX4 is a common driver of immune evasion and immunotherapy failure in metastatic cancers
por: Pineda, Jose Mario Bello, et al.
Publicado: (2023)

Correction to: In Situ Programming of CAR-T Cells: A Pressing Need in Modern Immunotherapy
por: Śledź, Marta, et al.
Publicado: (2023)

Current State of Immunotherapy and Mechanisms of Immune Evasion in Ewing Sarcoma and Osteosarcoma
por: Evdokimova, Valentina, et al.
Publicado: (2022)

CD8(+) T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy
por: Pourchet, Aldo, et al.
Publicado: (2016)

hrHPV E5 oncoprotein: immune evasion and related immunotherapies
por: de Freitas, Antonio Carlos, et al.
Publicado: (2017)

The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy
por: Cruz-Bermúdez, Alberto, et al.
Publicado: (2021)

Human immunology and immunotherapy: main achievements and challenges
por: Varadé, Jezabel, et al.
Publicado: (2020)

miR-301a mediated immune evasion by Japanese encephalitis virus
por: Hazra, Bibhabasu, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qj352mirn64g0kd2g56bf6p1er